About Laura

Laura Berezin is a member of Cooley's business department leadership team. She focuses her practice on corporate securities, M&A and complex corporate finance transactions, with a particular emphasis on representing clients in the life sciences industry. She represents public and private corporations, investment banks, venture capital funds, and financial institutions both in the United States and Europe in a variety of capital market transactions, including public offerings, private placements, PIPES and 144A transactions. Laura has extensive experience in representing life science companies in spin-outs and other domestic and cross-border M&A. Her general corporate practice includes formation and financing activities, securities compliance, public company disclosure and corporate governance matters. She also has extensive experience in counseling publicly-traded life sciences companies and their boards of directors. Laura has also served as a member of BIO's Emerging Company Governing Board. 

View full bio

Experience

SiteOne Therapeutics to Be Acquired by Eli Lilly for up to $1 Billion

SiteOne Therapeutics to Be Acquired by Eli Lilly for up to $1 Billion

May 28, 2025

Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.

Read more

Related contacts

Laura Berezin
Partner, Seattle
Sara Semnani
Partner, Santa Monica
Rowook Park
Partner, San Diego
Charity Williams
Partner, San Diego
Rena Kaminsky
Special Counsel, Palo Alto
Todd Gluth
Partner, San Diego
Lila Hope
Partner, Palo Alto
Noel Ripberger-Scheick
Associate, Palo Alto
Tucker Cochenour
Associate, Palo Alto
Kristin O'Hanlon
Special Counsel, San Francisco
David Fletcher
Partner, Washington, DC
Jamie Leigh
Partner, San Francisco
Carly Mitchell
Partner, Washington, DC
Jeremy Morrison
Partner, Washington, DC
Gerard O'Shea
Partner, New York
Marty Schenker
Senior Counsel , San Francisco
Chen Chen
Special Counsel, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Selin Akkan
Associate, Palo Alto
Mari Dugas
Associate, Washington, DC
Virat Gupta
Associate, Washington, DC
Joseph J. Kim
Associate, Palo Alto
Eileen Leman
Associate, Los Angeles
Ehijele Olumese
Associate, Santa Monica
Joseph Perry
Associate, Reston
Hannah Rausch
Associate, New York
Melody Van Horn
Senior Paralegal, Palo Alto

Related Practices & Industries

Mergers and Acquisitions
Capital Markets
Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Biotechnology
Compensation and Benefits
Cyber/Data/Privacy
Emerging Companies
Labor and Employment
Life Sciences and Healthcare Regulatory
Tax
Antitrust and Competition

SiteOne Therapeutics Announces $100 Million Series C

SiteOne Therapeutics Announces $100 Million Series C

December 18, 2024

Cooley advised SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough and other conditions, on its $100 million Series C financing.

Read more

Related contacts

Laura Berezin
Partner, Seattle
Sara Semnani
Partner, Santa Monica
Noel Ripberger-Scheick
Associate, Palo Alto
Annie Froehlich
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Tracy Rubin
Partner, Palo Alto
John Sellers
Senior Counsel, Palo Alto
Denny Won
Partner, San Francisco
Kimberly Nguyen
Special Counsel, Reston
Kristin O'Hanlon
Special Counsel, San Francisco
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Chen Chen
Special Counsel, Palo Alto
Michelle Liskanich
Associate, Santa Monica
Michael Gladstone
Associate, New York
Joseph J. Kim
Associate, Palo Alto
Sarah Oliai
Associate, Washington, DC
Ehijele Olumese
Associate, Santa Monica
Melody Van Horn
Senior Paralegal, Palo Alto
Katie Kissner
Quantitative Analyst, San Francisco

Related Practices & Industries

Life Sciences
Healthcare
Capital Markets
Emerging Companies
CFIUS
Cyber/Data/Privacy
Life Sciences and Healthcare Regulatory
Technology Transactions
Compensation and Benefits
Life Sciences Corporate Partnering and Licensing

Personalis Announces Expanded Collaboration With Tempus AI

Personalis Announces Expanded Collaboration With Tempus AI

August 16, 2024

Cooley advised Personalis, a company transforming the active management of cancer through breakthrough personalized testing, on its expanded commercial relationship with Tempus AI, including an equity investment by Tempus into Personalis.

Read more

Related contacts

Bill Roegge
Partner, New York
Laura Berezin
Partner, Seattle
Asa Henin
Partner, San Diego
Allison Peth
Associate, Palo Alto
Jeewon Lee
Associate, New York
Matthew Choy
Associate, New York
Megan Browdie
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC

Related Practices & Industries

Healthcare
Life Sciences
Mergers and Acquisitions
Life Sciences Corporate Partnering and Licensing
Antitrust and Competition
Securities Litigation + Enforcement

Bicycle Therapeutics – $555.5 Million Private Placement

Bicycle Therapeutics – $555.5 Million Private Placement

May 23, 2024

Cooley advised Bicycle Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of medicines referred to as Bicycle molecules, on its $555.5 million private placement offering. Partners Laura Berezin, Jaime Chase and Claire Keast-Butler led the Cooley team.

Related contacts

Laura Berezin
Partner, Seattle
Jaime L. Chase
Partner, Washington, DC
Claire Keast-Butler
Co-Partner in Charge – London, London
Dayne Brown
Associate, New York
Eric J. Delgado
Associate, New York
Jane Wang
Associate, New York

Related Practices & Industries

Capital Markets
Life Sciences

Kyverna Therapeutics Closes $85 Million Series B

Kyverna Therapeutics Closes $85 Million Series B

January 28, 2022

Cooley advised Kyverna Therapeutics on its $85 million Series B financing. Partners Laura Berezin and Sara Semnani led the Cooley team advising Kyverna, a developer of new cell-based therapeutics designed to offer treatments and cures for serious autoimmune and inflammatory diseases.

Related contacts

Laura Berezin
Partner, Seattle
Sara Semnani
Partner, Santa Monica
Han Wang
Associate, Santa Monica
Amy Lauren Saldamando
Manager of Capitalization Table Administration, Santa Monica

Related Practices & Industries

Emerging Companies
Venture Capital
View more

Admissions and credentials

California

Montana

Not admitted to practice in Washington

Rankings and accolades

Chambers USA: Life Sciences: Corporate/Commercial – California (2020 – 2025)

Best Lawyers in America: Lawyer of the Year: California (2023)

Best Lawyers: Lawyer of the Year – Securities Regulation (2021)

Best Lawyers in America: Biotechnology Law, Securities and Capital Markets Law and Securities Regulation

Best Lawyers: Lawyer of the Year – Biotechnology Law 

LMG Life Sciences Corporate Attorney of the Year (2018)

Legal 500 US: Life Sciences, Capital Markets and M&A: Venture Capital and Emerging Companies

PLC – Which Lawyer? Equity Capital Markets and Corporate Life Sciences

Daily Journal: Top 25 Biotech Lawyers in California (2011)